FP967 : Comparative Evaluation Tacrolimus 0.03% Vs 0.1% in Vernal keratoconjunctivitis as First Line Drug.

Dr.Rashmi kumari

To evaluate and compare the efficacy, side effects and recurrence rate of VKC with 0.03% and 0.1% Tacrolimus ,a prospective randomised double blinded comparative study was conducted.Sixty four patients of VKC between April 2015- July 2016 were enrolled and randomly treated with Tacrolimus eye ointment BD,0.03% in Group A or 0.1%in Group B for six months with fortnightly follow up.Main outcome measures were scoring and comparison of Total subjective symptom scores and Total objective ocular sign scores within and between the Groups at each follow up. Fifty two patients with comparable baseline characters were analysed. With treatment both TSSS and TOSS decreased consistently in both groups but an increase in scores was noticed at two weeks after drug withdrawl in Group A and at 6 weeks in Group B. Adverse effects scoring was more in Group B.Conclusion; Both concentrations of Tacrolimus are effective with higher( 0.1%) having better sustainability of effect but more side effects.